Journal of Cystic Fibrosis

Article	Citations
P402 Separation anxiety or a Kaftrio side effect? Implementation of cognitive behavioural therapy strategies with a young child with cystic fibrosis (CF): A clinical case study	285
P408 The halo effect in cystic fibrosis: when educated patients in turn educate their family carers	132
EPS10.07 Exacerbation characteristics and clinical outcomes in the elexacaftor/tezacaftor/ivacaftor era: same-same but different?	103
WS08.03 How does elexacaftor/tezacaftor/ivacaftor affect improvement in exercise capacity and body composition in adults with cystic fibrosis who have completed an exercise intervention?	96
P131 Effect of deprescribing from inhaled corticosteroids in people with cystic fibrosis: challenges & opportunities for a target trial emulation using the UK CF Registry	96
P296 Characteristics of carbohydrate metabolism disorders in children with cystic fibrosis in the Moscow region	90
P109 Safety of elexacaftor/tezacaftor/ivacaftor in patients 6 through 18 years with cystic fibrosis and at least one F508del allele: a retrospective Italian multicenter study	83
WS13.03 Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del	83
EPS10.06 Highly-effective CFTR modulation is associated with greater height and peak lung function in children with cystic fibrosis	76
EPS8.02 Evolving physiotherapy airway clearance technique (ACT) interventions during cystic fibrosis (CF) pregnancy in the variant specific therapy (VST) era	71
P172 Oscillometry: assessment of bronchial obstruction in children with cystic fibrosis	70
P078 Hyperacute response to cystic fibrosis transmembrane conductance regulator modulation	64
P227 Life threatening infection with a highly resistant Achromobacter xylosoxidans strain	60
Using heart rate data from wrist worn activity trackers to define thresholds for moderate to vigorous physical activity in children and young people with cystic fibrosis	60
P024 Analysis of the effect of cytochrome P450 genes polymorphism on the efficacy and safety of CFTR modulator therapy in cystic fibrosis	59
P478 Multiple breath inert gas wash out in infants and toddlers with cystic fibrosis before and after initiating inhaled hypertonic saline	58
Treatment of intestinal and liver features in cystic fibrosis mice by the osmotic laxative polyethylene glycol	57
“Mind the gap”- will we ever see equal median predicted survival for males and females in cystic fibrosis?	53
Contents	51
346 Leaky gut, dysbiosis, and inflammation support inter-organ communication in cystic fibrosis	50
WS15.05 Improvements in structural lung disease in people with CF aged 12 and above on elexacaftor/tezacaftor/ivacaftor are sustained for up to two years	50
258 Functional correction of CFTR-G542X in human bronchial epithelial cells using a Type I CRISPR adenine base editor with a guide-length- tunable editing window	47
97 Separability of membrane permeabilization and cell killing activities of the human host defense peptide LL-37 in Pseudomonas aeruginosa	47
652 Proteomics of bronchoalveolar lavage fluid in cystic fibrosis ferrets spontaneously colonized by Pseudomonas aeruginosa	45
252 Model systems to define tool LNP vehicles for the development of next generation therapies for Cystic Fibrosis	44

41 Loss of MexEF-OprN function increases virulence of clinical Pseudomonas aeruginosa isolates	44
634 Evaluating shared decision making in lung transplant discussions between clinicians and people with severe CF	42
78 Pseudomonas aeruginosa induced GM-CSF production by airway epithelial cells could help protect against Mycobacterium abscessus	42
729 Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on healthcare resource utilization (HCRU) over three years in LONGITUDE – a UK CF Registry observational study	41
523 Navigating school with cystic fibrosis: perspectives of people with CF and their caregivers	41
748 Development of metabolic syndrome in people with cystic fibrosis after three years of elexacaftor/tezacaftor/ivacaftor	41
496 Pilot and feasibility study of an individualized telehealth exercise program in CF patients	41
475 Physiologically based pharmacokinetic of elexacaftor/tezacaftor/ ivacaftor in children with cystic fibrosis: extrapolation of the dosing regimen in children under 2 years of age	40
279 Simultaneous inhibition of DNA-PKcs and 53BP1 enables the enrichment-free replacement of the CFTR cDNA in airway basal stem cells	40
757 The impacts of highly effective modulator therapy and telehealth on cystic fibrosis care: Changes in visit frequency	40
379 Identifying and prioritizing burdens of cystic fibrosis care for Canadians living with CF	40
48 Small airway epithelial cells in M. abscessus infection: Implications for inflammation and epithelial barrier integrity	37
34 Regulation of an epoxide-based virulence factor in Pseudomonas aeruginosa	37
786 Use of aerobic exercise for airway clearance in a pediatric CF care center	36
241 Functional characterization of an ex vivo ferret model as a precursor for cell therapy	36
203 Airway dysanapsis is associated with residual pulmonary exacerbation risk in children with cystic fibrosis treated with elexacaftor/tezacaftor/ ivacaftor	36
165 IL-21 and IL-21R interaction plays a key role in mounting humoral and cell-mediated immune response to adenoviral and adeno-associated viral vectors in lung	35
325 Evaluation of CFTR gene editing efficacy using patient-derived nose- on-chip model	34
22 The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studies	34
227 Nascent chain misfolding slows translation and stimulates co- translational mRNA decay	33
Theranostics vs theratyping or theranostics plus theratyping?	31
209 Inositol-requiring enzyme 1β is a therapeutic target for cystic fibrosis airway muco-obstructive disease	31
Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort	31
564 “How do you live the best life you can with this pain?” A qualitative study of the challenges of living with CF and pain in the modulator era	31
235 Differential regulation of immune function by highly effective CFTR modulators in THP-1-derived macrophages	30
679 Effect of hybrid closed loop insulin delivery on glycemic control in adolescents and adults with cystic fibrosis-related diabetes	29
184 Bioengineered three-dimensional cystic fibrosis lung airway model for drug testing	29
808 Implementation of physical therapy and exercise education in annual cystic fibrosis clinic	28
365 Differential effects of (S)- and (R)-vanzacaftor on BKCa potentiation and CFTR correction	28
39 Using mouse models to understand the critical roles of granulocyte macrophage colony stimulating factor and macrophages for control of pulmonary Mycobacterium abscessus infection	28
260 RCT2100 rescue of cystic fibrosis (CF) transmembrane conductance regulator function in CF human bronchial epithelial cells and mucociliary clearance in CF ferrets	28
27 Standing up to the “bully”: Staphylococcus aureus can sustain long-term infection in the presence of Pseudomonas aeruginosa and may outcompete in the cystic fibrosis airway	27
99 Development and validation of a deep neural network to predict antimicrobial resistance in people with cystic fibrosis using routinely collected electronic healthcare record data	27
490 What are the experiences of cystic fibrosis clinical nurse specialists? Are systemic practice ideas unknowingly incorporated when working with children and families?	26
644 Timely initiation of pancreatic enzyme replacement therapy for surgical cystic fibrosis infants in the neonatal intensive care unit	25
526 Non-surgical management of urinary incontinence in women with cystic fibrosis	25
529 Are adults with cystic fibrosis choosing to continue with airway clearance therapy in the era of highly effective gene modulator therapy?	25
320 Gain-of-function CFTR mutation improves function of W1282X CFTR	25
558 Challenges faced by parents of children with cystic fibrosis in Ireland: The Irish Comparative Outcome Study of Cystic Fibrosis	25
304 Assessing a novel dual-endonuclease system in restoring CFTR expression in cystic fibrosis humanized mouse and human airway models	25
586 Description of a novel therapeutic support group for siblings of children with cystic fibrosis: Siblings Supporting Others and Achieving Resilience	24
Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor	24
773 A quality improvement project to improve the evaluation of low bone density in people with cystic fibrosis	24
Neurovascular complications post bronchial artery embolisation in patients with cystic fibrosis. A 7-year single centre retrospective review	24
480 Weight stigma among healthcare professionals treating CF in North America	24
Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation	24
Evidence for secondary ciliary dyskinesia in patients with cystic fibrosis	24
P118 Community engagement and involvement in clinical trials and beyond…	23
P081 Elezacaftor/tezacaftor/ivacaftor therapy and quality of life in children and their caregivers	23
P352 Effect of ACE, ACTN3, PPARA, PPARGC1A gene polymorphisms on nutritional status in patients with cystic fibrosis in the Russian Federation	23

WS14.01Primary nasal epithelial cells for personalized medicine in non-eligible cystic fibrosis patients	23
P104 CF-AMR Syndicate Collaborative Discovery Programme to accelerate the development of antimicrobials to treat lung infections in cystic fibrosis	23
WS10.02Proteomic analysis of nasal lavage fluid and sputum samples in people with cystic fibrosis during 24 months of treatment with elexecaftor/tezacaftor/ivacaftor - The RECOVER study	23
P379 TIDES 2.0: prevalence and longitudinal course of depression, anxiety, and behaviour problems in children with cystic fibrosis (CF) under 12 years of age	23
P159 Long COVID in people with cystic fibrosis: a prospective observational study within the Italian Cystic Fibrosis Society	22
P174 A retrospective review of lung ultrasound in guiding physiotherapy input for people with cystic fibrosis in an in-patient setting	22
P223 The role of horizontal Gene transfer in the development of resistance in Achromobacter ruhlandii	22
P278 Trends in paediatric bone mineral density 2016-2024 – a single centre study	22
P046 Investigating the safety of elexacaftor/tezacaftor/ivacaftor exposure during early development	21
P033 The impact of newborn bloodspot screening program modification in 2023 on the time of diagnosis in cystic fibrosis patients and follow-up care	21
P418 Recalibrating “a whole new life”: exploring the impact of elexacaftor/tezacaftor/ivacaftor on self-concept for adults with cystic fibrosis	21
P421 Accessing impact of elexacaftor/tezacaftor/ivacaftor therapy on antidepressant usage in an adult cystic fibrosis population	21
P341 Body composition and handgrip strength among children and adolescents with cystic fibrosis: correlation with anthropometric parameters and disease severity	21
P308 Effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycaemic control in children with cystic fibrosis: a promising trend towards improved glucose regulation	21
Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location	20
P249 Aspergillus fumigatus prevalence in Georgian paediatric cystic fibrosis patients	20
508: Extracellular vesicles mediate bacteria–immune cell interactions in the respiratory tract	20
465: Intestinal function and transit relates to microbial dysbiosis in the CF gut	19
140: Oh gee! Time tested OGTT annual screening improvement: A single-center experience	19
ePS2.02 Comparison of FEV on a remote spirometry device with hospital software in an adult cystic fibrosis cohort	19
353: Electrolyte transport properties assay revealed less carbachol-stimulated short-circuit current in cultured human small airway epithelia	19
488: Bile acids, bacterial colonization, and lung inflammatory markers in infants with cystic fibrosis	19
314: The COVID-19 pandemic and trends in anxiety and depressive symptoms in adolescents with cystic fibrosis and their caregivers	19
306: Behavioral health resources and screening in military cystic fibrosis centers: A survey	19
670: F508del and G542X sheep models exhibit a severe cystic fibrosis phenotype, and their tracheal epithelial cells respond to human therapeutics in vitro	19
568: Quantifying regional pulmonary ventilation changes pre-/postivacaftor treatment in same subject using hyperpolarized 3He MRI	19
620: Iterative screen identifies amphiphilic peptides that confer enhanced delivery of CRISPR-associated nucleases and adenine base editors to airway epithelia	19
P029 Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 2789+5 G-to-A splicing mutation	19
463: Clearance of colonized bacterial species in CF patients before and after elexacaftor/tezacaftor/ivacaftor	19
5: Testosterone deficiency in men with cystic fibrosis: Understanding prevalence & association with clinical outcomes	19
220: Using lean methodologies to influence oral glucose tolerance test completion in cystic fibrosis patients	18
257 Rapid health decline in young cystic fibrosis transmembrane conductance regulatorG551D ferrets after discontinuation of cystic fibrosis transmembrane conductance regulator modulator	18
460: Prevalence of antimicrobial resistance mutations in Mycobacterium abscessus and associations with in vitro susceptibility testing	18
When CFSPID becomes CF	18
585: Development of a novel, cell-free, in vitro, high-throughput screening system for readthrough agents of nonsense mutations	18
ePS3.05 Induced levofloxacin resistance persists in evolved lineages of Pseudomonas aeruginosa isolates from people with cystic fibrosis after exposure to other inhaled antibiotics	18
148: Sustainably implementing impactful pre-visit planning using the electronic health record	17
P052 Introduction of an innovative “pill-swallowing school” in a cystic fibrosis paediatric population within a tertiary centre	17
P106 Upper airway disease in adults with cystic fibrosis: a cross-sectional study	17
P143 Bronchopulmonary infection/colonisation in Spanish cystic fibrosis patients: preliminary results of a multicentre study	17
WS11.04 Confirmatory genetic testing for all cystic fibrosis screen positive newborns: a 12-year analysis	17
WS03.03 Qualitative analyses of the experiences of people with end-stage cystic fibrosis lung disease receiving ELX/TEZ/IVA	17
P083 Decreased respiratory burst in circulating neutrophils after initiation of CFTR modulator therapy in cystic fibrosis patients with chronic lung infections	17
145 Prescription of elexacaftor/tezacaftor/ ivacaftor in lung transplant recipients with cystic fibrosis	17
WS10.03 Impact of triple CFTR modulator therapy on urinary incontinence symptoms in adults with cystic fibrosis	17
WS11.03 Repeated sweat testing in children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)	17
P209 Physical fitness and habitual physical activity in children with cystic fibrosis - do they improve with elexacaftor/tezacaftor/ivacaftor therapy?	17
ePS4.03 Outcomes of COVID-19 in patients with cystic fibrosis in Wales, UK	17
447 Mucociliary interactions and the vertical clearance assay 2.0	17
341 Improving care for pregnant people with cystic fibrosis by increasing knowledge of obstetric providers	16
P243 The effect of hypoxic conditions on Burkholderia cenocepacia clinical isolates from individuals with cystic fibrosis	16
633 Extracellular vesicles as delivery vectors to enhance killing of bacteria and viruses by airway-recruited human neutrophils	16
P221 Tension-free vaginal tape – a 15-year review of effect on urinary incontinence in patients with cystic fibrosis	16
332 Vocational rehabilitation services for people with cystic fibrosis: Predictors of employment outcomes	16
59 Improving mycobacterial sputum culture collection in adult patients during the highly effective modulator therapy era	16
EPS5.08 Elexacaftor/tezacaftor/ ivacaftor reduces need for pancreatic enzymes, enteral feeding and omeprazole use without causing excessive weight gain: a 2-year observational study	16
487 Evaluating use of doxycycline versus vancomycin for treatment of methicillin-resistant Staphylococcus aureus–associated acute pulmonary exacerbations in people with cystic fibrosis	16
Structure basis of CFTR folding, function and pharmacology	16
P418 Patient satisfaction and clinical effectiveness of using the I-neb in children with cystic fibrosis (CF) in Wales	16
51 Outcomes after SARS-CoV-2 infection in Canadians with cystic fibrosis: Analyses using the Canadian Cystic Fibrosis Registry	16
P282 Implementing routine assessment of gastrointestinal outcome measures in the cystic fibrosis clinic	16
P360 Mental health in cystic fibrosis patients: predictive factors and psychopathology	16
291 Development and validation of the Cystic Fibrosis Stress Questionnaire: A cystic fibrosis–specific measure of perceived stress	16
European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance	16
132 Respiratory symptom changes during menstrual cycles in women with cystic fibrosis	16
Preclinical atherosclerosis in cystic fibrosis: Two distinct presentations are related to pancreatic status	16
419 Role of macrophage cystic fibrosis transmembrane conductance regulator in lung inflammation	16
348 Single-cell multi-omics profiling reveals novel regulatory networks of CFTR in the kidney	15
329 Intrinsic conformational dynamics required for CFTR gating cycle revealed by single-molecule Förster resonance energy transfer	15
P007 Experience of using intestinal current measurement (ICM) in Russia	15
558 Development of a gene editing strategy to treat cystic fibrosisassociated liver disease	15
372 Cystic fibrosis does exist in India! A successful approach to education and improving awareness of cystic fibrosis of physicians and caregivers in India	15
249 Pharmacological rescue of CFTR premature termination codon mutations by novel small molecules	15
Restoring airway epithelial homeostasis in Cystic Fibrosis	15
P295 The results of colorectal cancer screening in patients with cystic fibrosis in Wales	15
Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas	15
WS19.01 Non-adherence in the twilight zone: the complexity of complex medications	15
P387 Reviews and outcomes from a new pregnancy support service at a large cystic fibrosis centre	15
462 Cystic fibrosis mental health and wellness questionnaire—factors and properties	15
WS06.03 A real-world evaluation of remote monitoring in cystic fibrosis care: a mixed-methods multicentre observational study	14

P382 Cystic fibrosis and disordered eating behaviour: a collaborative approach to improve care	14
624 Evaluating precision medicine tools in cystic fibrosis for racial and ethnic fairness	14
100 Vancomycin demonstrates activity against Mycobacterium abscessus in combination with guideline-recommended antibiotics under physiologically relevant stress conditions	14
260 Cystic fibrosis transmembrane conductance regulator modulator–associated liver inflammation in pediatric cystic fibrosis	14
43 Bacteriophages that kill Pseudomonas aeruginosa induce heterogenous cellular responses in the airway epithelium	14
417 Resolvin D1 reduces cystic fibrosis lung disease and inflammation associated with mucus obstruction	14
P104 The dynamics of health of children with cystic fibrosis in Russian Federation according to the registry data during last 10 years	14
P169 Vitamin absorption after the introduction of elexacaftor/tezacaftor/ivacaftor in children and adolescents diagnosed with cystic fibrosis	14
Sexual and reproductive health experiences and care of adult women with cystic fibrosis	13
P017 The role of the VDR gene in the formation of clinical manifestations and complications in cystic fibrosis	13
Serological biomarkers for the diagnosis of Mycobacterium abscessus infections in cystic fibrosis patients	13
P219 Otorhinolaryngologic, audiological and genetic findings in children with cystic fibrosis: a tertiary care experience	13
WS13.01 The cystic fibrosis Home Sputum-Induction Trial (CF-HomeSpIT - ISRCTN86523335) to evaluate home sputum-induction and early morning saliva sampling in children with cystic fibrosis	13
647 Impact of newborn screening program with NextGen sequencing on direct patient care	13
292 Mechanism of CFTR modulation on endothelial mechanosensitive channels	13
288 CFTR genetic variants and association with cancer	13
P134 Evaluation of multidisciplinary ambulatory care cost among children with cystic fibrosis: a comparative study between cystic fibrosis centers in Ireland and the United States	13
13 Extended-interval dosing of amikacin against Mycobacterium abscessus reduces efficacy in vitro	13
491 The Cystic Fibrosis Questionnaire–Revised and body image in adults in the era of elexacaftor-tezacaftor-ivacaftor	13
11 Examining antibiotic regimen spectrum and clinical outcomes of pulmonary exacerbation treatment	12
524 Acid suppression therapy and associations with growth, gut microbiome, and early-onset lung disease in young children with cystic fibrosis	12
Contents	12
P006 False negative newborn screen and absent clinical features of cystic fibrosis after in utero modulator exposure for an infant with two cystic fibrosis causing mutations	12
Improved early growth in Danish children with cystic fibrosis from 2000-2022	12
54 Recombinant pyocins as emerging therapies against respiratory infections with Pseudomonas aeruginosa	12
Autoimmunity in people with cystic fibrosis	12
P462 Applicability of A-STEP performance test in patients diagnosed with cystic fibrosis in Turkish population	12
Risk factors for cystic fibrosis arthropathy: Data from the German cystic fibrosis registry	12
314 A role for CFTR in pancreatitis	12
410 Multidisciplinary collaboration for transition readiness and planning	12
Personalized therapy with CFTR modulators: Response of p.Ile148Asn variant	12
P460 Assessing the exercise capacity of adolescents with cystic fibrosis in the post elexacaftor/tezacaftor/ivacaftor era, via cardiopulmonary exercise test	12
Implementation of standardized cystic fibrosis care algorithm to improve the center data-quality improvement project international collaboration	11
P229 Do CFTR modulators interfere with microbiological diagnosis?	11
P316 Increasing numbers of pregnancies due to modulator therapy in cystic fibrosis	11
EPS10.10 Elexacaftor/tezacaftor/ivacaftor remains inaccessible for people with cystic fibrosis in low- and middle-income countries: how can this be solved?	11
P236 Investigating the impact of elexacaftor/tezacaftor/ivacaftor therapy on longitudinal oropharyngeal microbiome dynamics in children with cystic fibrosis	11
Long-term outcomes in people with CF lacking FEV1 response to elexacaftor/tezacaftor/ivacaftor therapy	11
P052 Real-life experience with a generic formulation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and responsive CFTR variants with previous modulators therapy	11
P280 Rapid review of the outcome measures and endpoints used to measure gastrointestinal disease in cystic fibrosis (CARDS-CF study)	11
Contents Page	11
P357 Effect of elexacaftor/tezacaftor/ivacaftor on metabolic parameters and body weight in patients with cystic fibrosis: a five case series with oneyear follow-up	11
P262 Lack of association between antibiotic regimen spectrum and pulmonary exacerbation treatment responses	11
WS08.04 Assessment of functional exercise capacity using telehealth: reliability, validity, and usability in children with cystic fibrosis	11
P363 A retrospective review of fat-soluble vitamins A, D and E levels and vitamin supplementation in a cystic fibrosis (CF) maternal health population	11
P306 Analysis risk factors for the decrease bone mineral density in cystic fibrosis	11
P125 Development of a holistic feedback package to support quality improvement in cystic fibrosis centres in the UK	11
P359 The impact of elexacfator/tezacaftor/ivacaftor on the weight trajectories of children and adolescents and predictive factors	11
P099 The London CTAP network standard operating procedure for averting medications prohibited during clinical trials in cystic fibrosis	10
45 Development of a co-culture model for secondary screening of candidate anti-microbial compounds targeting persistent lung infections in cystic fibrosis	10
607 Evidence of protease dose-response in a Phase 1 trial of ANG003, a non-porcine pancreatic enzyme replacement therapy	10
469 Impact of social complexity on long-term health outcomes and survival in young adults with cystic fibrosis	10
470 Implementing annual collection of self-reported patient demographic information	10
326 Generation of a robust CFTR-specific immunolabeling protocol	10
P258 Development of a liquid polymicrobial biofilm model for preclinical testing of novel cystic fibrosis therapeutics	10
513 Elexacaftor/tezacaftor/ivacaftor dose reduction leads to resolution of clinical adverse events without a significant effect on sweat chloride or FEV1	10
P275 Utility of adding gamma-glutamyl transpeptidase to platelet ratio to cystic fibrosis related liver disease screening	10
636 Characterizing use of acid-suppressing medications and foregut gastrointestinal testing in advanced cystic fibrosis lung disease in cystic fibrosis centers	10
65 Thymic stromal lymphopoietin and IL-33 alarmin cytokine production by primary human cystic fibrosis lung macrophages is induced by infection with Pseudomonas aeruginosa and further increased by CFT	10
489 Journey mapping of barriers to transitioning to adult CF care	10
P424 Totally implantable venous access devices (TIVADs) flushing intervals: where are we?	10
WS05.04 SPL84 efficient and durable effect, restoring 3849 +10 kb C-to-T mutated CFTR, when treated through the apical side of primary HBE cells	10
P323 Gastrointestinal health through self-reported assessment in children with cystic fibrosis	10
628 Esophagogastroduodenoscopy findings in adults with cystic fibrosis: implications for screening and management	10
49 Differential effects of cationic antimicrobials on intrinsic antibiotic resistance in Pseudomonas aeruginosa	10
551 Integration of psychosocial screening tool into routine care of children with CF: Results of a 1-year pilot study and lessons learned	10
330 Rescue of CFTR nonsense mutations is enhanced under inflammatory stimuli	10
P123 Establishing a cystic fibrosis learning network for low and middleincome countries	10
211 Characterization of airway submucosal gland hypertrophy in cystic fibrosis	9
183 Adenylate cyclase 6 is required for cyclic adenosine monophosphate–dependent activation of CFTR to regulate mucociliary clearance in cystic fibrosis airways	9
207 Enhancing apical loop currents in airway epithelia carrying minimal function CFTR mutations	9
650 Single-center cohort study evaluating quality of colonoscopy bowel preparation in adults with cystic fibrosis	9
344 Transgene expression and CFTR channel function in human bronchial epithelial cells after addition of CFTR modulators and 4D-710	9
308 Ligand-free biodegradable poly(beta-amino ester) nanoparticles for targeted systemic delivery of mRNA to the lungs	9
309 Pulmonary ionocytes regulate chloride secretion and absorption via CFTR	9
87 Activity of β-lactams and new β-lactamase inhibitors in multidrug-resistant Burkholderia contaminans	9
693 Machine learning analysis of continuous glucose monitoring after elexacaftor/tezacaftor/ivacaftor initiation in young children predicts dysglycemia better than an oral glucose tolerance test	9
680 Effects of elexacaftor/tezacaftor/ivacaftor on growth and puberty in children with cystic fibrosis	9
38 ACE-1b, a novel anti-infective conjugated electrolyte, effectively controls nontuberculous mycobacterial infections	9
865 Elexacaftor/tezacaftor/ivacaftor concentrations are similar in transplanted and non-transplanted people with CF	9
4 Within-lung interspecies gene transfer causes rapid evolution of extreme antibiotic resistance in cystic fibrosis	9
75 Improvements in nutritional status, lung function, and respiratory cultures in pediatric cystic fibrosis after starting elexacaftor/tezacaftor/ivacaftor therapy: A real-world, multicenter study	9
182 IL-21R and IL-21 play a crucial role in modulating B and T cell immune responses to viral gene therapy vectors in the lungs	9
233 Altered role of septins in Pseudomonas aeruginosa intracellular infection of cystic fibrosis bronchial epithelial cells	9
716 Pilot screening prediction model for late-diagnosed cystic fibrosis	9
403 Exploring CFTR variants: implications for exocrine pancreatic diseases	9
817 Harnessing the power of the electronic medical record to implement the new cystic fibrosis liver disease guidelines	9
394 Elexacaftor/tezacaftor/ivacaftor interferes with hippocampal neurotransmission in mice	9
Coping and learning to Manage Stress with cystic fibrosis (CALM): A multisite telehealth randomized controlled trial to reduce depression and anxiety symptoms in adults with cystic fibrosis	8
WS08.02Specific Pseudomonas aeruginosa IgG levels before and after elexacaftor/tezacaftor/ivacaftor treatment	8
Prevalence, Risk Factors, and Sequelae of Asymptomatic Clostridioides difficile Colonization in Children with Cystic Fibrosis	8
P124 The role of forced oscillometry technique in monitoring lung function of paediatric cystic fibrosis patients on elexacaftor/tezacaftor/ivacaftor therapy	8
423 Impact of new GLI equations on study eligibility, a retrospective	8
P373 Does visualising lung function and Body mass index (BMI) trends using the ‘My report’ section on the cystic fibrosis registry database help clinical decision making and improve the patient experi	8
Infection prevention and control in cystic fibrosis: An update of a systematic review of interventions	8